Get started

Drugs

New long hold for good startup Biopharma companyWithout looking at the news, the CNTB should have gone down to get more air and stay around the $1.6 zone to be attractive. However, the new news regarding Simcere obtained the exclusive deal with CNTB regarding phase 3 drug rademikibart providing CNTB immediate big funding ($21M-$121M). This may signal a very bullish run if the market receives this news as excitement. The CNTB is still able to develop and commercialize rademikibart elsewhere aside from the greater China region (China, Hong Kong, Taiwan, Macau). We detect here a Cup and handle patterns and suspect there would be a breakthrough ceiling at $2.83 after rallying around $2.5. This is not financial advice but my view on CNTB at the current time!
NASDAQ:CNTBLong
by Haizsama
1
Weight loss - Stock GainEli Lilly & Co. is a pharmaceutical company with a long history dating back to its founding by Eli Lilly in May 1876. The company is headquartered in Indianapolis, Indiana, and is engaged in the discovery, development, manufacture, and sale of pharmaceutical products. Their product portfolio includes a range of therapies in various therapeutic areas, such as diabetes, oncology, immunology, neuroscience, and other medical conditions. One notable aspect of their recent success is the introduction of a weight loss drug, tirzepatide. This drug is similar to other medications like Ozempic and Wegovy, which are also designed to help with weight loss. These medications are administered via weekly injections and work by affecting the patient's appetite by mimicking certain hormones in the gut. Wegovy, for instance, primarily mimics the hunger-regulating hormone called GLP-1, while tirzepatide goes a step further by mimicking both GLP-1 and another hormone called GIP. These hormonal effects can lead to decreased appetite, making it easier for individuals to manage their weight.
NYSE:LLYLong
by Helios_Capital_Investment
Psychemedics PMD micro-cap Due For Bullish Reversal Cycle 5% Dividend Yield, with 100% upside Share Potential The world’s largest provider of hair testing for drugs of abuse announced financial results for the first quarter ended March 31, 2023 And the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023 The Company’s revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last year. Psychemedics Corporation is a United States corporation which provides patented, FDA-cleared, CAP certified clinical laboratory services for the detection of drugs of abuse. The company's corporate headquarters are located in Acton, Massachusetts and its laboratory operations are located in Culver City, California. Wikipedia
NASDAQ:PMDLong
by noam_chom
ABBV | Loading this Drug Company | LONGAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
NYSE:ABBVLong
by DivergenceSeeker
2
Healthcare leader $PRGO making a shark pattern Perrigo is in the Medical-Generic Drugs Group, they develop, manufactures, markets, and distributes private label self-care products, including cough, cold, and allergy products, analgesics, gastrointestinal products, smoking cessation products, infant formula and food products. IBD gives it a #1 rank in its industry. PRGO made its major low in May while XLV made it in late June. That's very good relative strength. Now, after the price broke above its 200-day MA, its been forming a base giving a good opportunity to buy. The price is making shark pattern with a pivot buy at $43.01. I'll leave a STOP BUY at that level.
NYSE:PRGOLong
by dpuleo19
Galapagos (GLPG.as) bearish scenario:The technical figure Triangle can be found in the Belgium company Galapagos NV (GLPG.as) at daily chart. Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. The Triangle has broken through the support line on 26/07/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 7 days towards 45.00 EUR. Your stop loss order according to experts should be placed at 56.70 EUR if you decide to enter this position. Galapagos agreed to acquire CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities. Galapagos will pay an upfront amount of €125 million for CellPoint, an additional €100 million to be paid upon achieving certain milestones, and $14 million for AboundBio. Galapagos said that, through the acquisition of CellPoint and AboundBio, it gains access to an automated point-of-care cell therapy supply model and a next-generation fully human antibody-based therapeutics platform. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:GLPGShort
by legacyFXofficial
The big "Legalize It"Fundamentals: + Weed + Established pharma and re-creational contacts. + Key moment for the "Legalize it" movement Opinion: Cron and Aurora canabis are the main names in the publicly traded cannabis's industry. As governments attempt to fight inflation while walking the recession line, it becomes a "Win-Win" for legalization and governments. A number of countries still have restrictions on cannabis but whilst fighting inflation and hunting for taxable income, the next 24 months may prove to be the most legaly accommodating towards this new industry. This week Thailand made the move. The idea is that they wont be the last! #Long Notes on how I personally use my charts/NFA: Each level L1-L3 and TP1-TP3 has a deployment percentage. The idea is to flag these levels so I can buy 11% at L1 , 28% at L2 and if L3 deploy 61% of assigned dry powder. The same in reverse goes for TP. TP1: 61%, TP2:28% and TP3:11%. If chart pivots between TP's, in-between or in Between Sell levels these percentages are still respected. I like to use the trading range to accumulate by using this tactic. Just my personal way of using this. This is not intended or made to constitute any financial advice. This is not intended or made to constitute any financial advice. FED Macro Situation Consideration: All TP's are drawn within the context of a return to FED neutral policy. I do not expect these levels to be reached before tightening is over. NOT INVESTMENT ADVICE I am not a financial advisor. The Content in this TradingView Idea is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained within this idea constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments in this or in in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All Content on this idea post is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the idea/post constitutes professional and/or financial advice, nor does any information on the idea/post constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. You alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other Content on the idea/post before making any decisions based on such information.
NASDAQ:CRONLong
by TheBitcoinGeneration
1
Novartis AG (NOVN.vx) bearish scenario:The technical figure Triangle can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine (Lamisil), deferasirox (Exjade), and others. The Triangle has broken through the support line on 03/05/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 12 days towards 80.160 CHF. Your stop loss order according to experts should be placed at 87.480 CHF if you decide to enter this position. Novartis said earnings and sales rose in the first quarter of the year, boosted by its key drugs, including heart failure treatment Entresto. Net income was $2.2 billion, up from $1.8 billion in the same quarter the previous year, on sales that grew to $12.53 billion from $12.41 billion. Analysts expected sales of $12.62 billion. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
SIX:NOVNShort
by legacyFXofficial
2
Novartis (NOVN.vx) bullish scenario:The technical figure Double Bottom can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), deferasirox (Exjade), and others. The Double Bottom has broken through the resistance line on 07/04/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 29 days towards 86.88 CHF. Your stop-loss order according to experts should be placed at 72.50 CHF if you decide to enter this position. Novartis CEO Vas Narasimhan is continuing his shake-up of the giant Swiss drugmaker, announcing a corporate restructuring on Monday that the company says will simplify its organizational chart and bring more than $1 billion in annual savings. Novartis AG NVS announced that the FDA has approved its kinase inhibitor, Vijoice (alpelisib), for the treatment of patients aged two years and above with severe manifestations of PIK3CA-Related Overgrowth Spectrum (“PROS”), requiring systemic therapy. Per the company, following the nod, Vijoice became the first FDA-approved therapy to treat PROS, which includes rare conditions where overgrowths and blood vessel anomalies occur. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
SIX:NOVNLong
by legacyFXofficial
Bayer AG (BAYN.de) bullish scenario:The technical figure Channel Down can be found in the German company Bayer AG (BAYN.de) at daily chart. Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds, and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index. The Channel Down has broken through the resistance line on 12/01/2021, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 49 days towards 54.270 EUR. Your stop loss order according to experts should be placed at 43.905 EUR if you decide to enter this position. Bayer AG on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts. Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements. The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
MRK has a lot of headline potential from hereHeadline Potential Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug: Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant Vaxneuvance, a pneumococcal vaccine Lynparza, a breast cancer drug Merck also continues to make strong headway with Keytruda, an immunotherapy, which recently picked up another approval in Japan. All of this means that Merck has a lot of headline potential in coming weeks, especially at a time when a new Covid-19 variant is spreading across the world. There's quite a bit of options activity in Merck today as traders place bets ahead of the news. Technicals and Sentiment Merck is currently near support from a long-term trend line and from the 200-day EMA. It has 26% upside to the average analyst price target and a bullish put/call ratio of .43. It has an average analyst rating of 9.3/10, which is very high. It gets an above average ESG score of 2.25/3. Value S&P Global gives Merck's fundamentals an average score of 90/100. IIt's currently trading -1.4 standard deviations below where it usually trades in relation to its major moving averages. Forward dividend yield is about 3.7%, forward P/E just over 11, forward P/S about 3.4. The price to free cash flow ratio is fairly high, at over 20, but that has to be interpreted in light of the other multiples. estimate that Merck has about 18% upside to its average price multiple of the last 3 years. Its earnings outlook is highly positive; I score its growth forecast a 5/6.
NYSE:MRKLong
by ChristopherCarrollSmith
9
NUMI Daily 26 EMA Re-test; Potential Hourly Bear FlagMy alert for NUMI's daily 12 EMA went off 12/21/2020 and have a tiny entry there. Wanted to add more to the 26 EMA (left) but missed it and it's seeing a solid 10-12% bounce from that. Hourly chart (right) looks like it could be setting up an hourly bear flag which has me cautious here. My position is very tiny; if doing swing trades on penny stocks I think it's key to size appropriately, relative to a day-trade position.
NLong
by cryptochemistry
Merck a strong value with strong technicals and upcoming newsI've been holding Merck since its big dip to $76 back in June. At the time I set a price target of $82: However, I didn't sell at $82 and have continued to hold the stock due to strong fundamentals, technicals, news, and sentiment. Merck has positive earnings and sales growth, with PEG ratio of 1.7 and PSG ratio of 2.3. It has a nice dividend yield at 2.9%, a rarity for a stock with such strong growth. Analysts rate it highly, with an average score of 80.25/100 from S&P Global and an Equity Starmine Summary Score of 8.5/10. With a put/call ratio of 0.41, sentiment on Merck is stronger than on most of the other stocks I watch. It's got a good ESG score and a long history of beating analyst estimates. Plus it's poised to benefit from some hype around its antiviral drug intended to fight Covid-19 that starts clinical trials in September. In technical terms, Merck recently broke out of a triangle, got a couple bullish moving average crosses, and today broke out above its recent trading range. If Merck oscillates down to its moving averages, I may use that as an opportunity to add to my position. I think the stock still has plenty of upside, especially when the clinical trial headlines start to hit.
NYSE:MRKLong
by ChristopherCarrollSmith
ABBV buy the dip ahead of pharma seasonAbbvie's volume has slackened somewhat after its recent triangle breakout, and it has broken its steep upward trendline. We may see a small correction late this month as Abbvie pulls back toward triangle top. However, if healthcare and pharmaceutical sector earnings continue to deliver this month (as they have so far), then Abbvie should get some buying volume along with the rest of the sector. And then in August, a period of seasonal pharmaceutical strength begins. In The Stock Traders' Almanac, Jeffrey Hirsch makes an extensive study of seasonal stock market performance by sectors. His third-best-performing seasonal trade by average 10-year return (16.8%) is to go long biotech from early August to early March. I believe that's because this is the busy season for FDA drug application reviews. The pharma sector does have an unusual level of political risk this year. Democrats have traditionally been hard on the pharma sector, and they look poised this year for a sweep. If the polls remain strongly blue, then we might see pharma underperform this year. That said, I think a lot of the political risk is already priced in. Whereas most of the stocks I look at are at the very top of their 3-year valuation range in terms of forward earnings and sales, pharmaceutical companies like Abbvie and Merck are trading in the bottom quartile of their 3-year valuation range. With forward PEG ratio around 2, forward PSG ratio around 0.5, and a whopping 5% dividend, Abbvie looks really attractively valued. I've been doing a lot of deal-hunting lately, and this is one of the only stocks I've seen with both a strong growth story and a valuation I really like. The analysts and options traders like it too; Abbvie has a 9.9/10 Equity Starmine Summary Score, and near-dated options positions are heavily skewed toward calls.
NYSE:ABBVLong
by ChristopherCarrollSmith
1
OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good. *1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer. *$21 Million cash on hand with burn rate of less than 10 Million per year. *This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million. Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
AMEX:OGENLong
by TheStockMarketSniper
1
VBI vaccines $4 EOY Target Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020 Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020 Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020 Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020 11 Million shares bought by insider www.sec.gov
VLong
by jfs2152
2